Blunted sFasL signalling exacerbates TNF‐driven neutrophil necroptosis in critically ill COVID‐19 patients

Objectives Critically ill coronavirus disease 2019 (COVID‐19) patients are characterised by a severely dysregulated cytokine profile and elevated neutrophil counts, impacting disease severity. However, it remains unclear how neutrophils contribute to pathophysiology during COVID‐19. Here, we assesse...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical & translational immunology 2021, Vol.10 (12), p.e1357-n/a, Article 1357
Hauptverfasser: Schweizer, Tiziano A, Mairpady Shambat, Srikanth, Vulin, Clement, Hoeller, Sylvia, Acevedo, Claudio, Huemer, Markus, Gomez‐Mejia, Alejandro, Chang, Chun‐Chi, Baum, Jeruscha, Hertegonne, Sanne, Hitz, Eva, Scheier, Thomas C, Hofmaenner, Daniel A, Buehler, Philipp K, Moch, Holger, Schuepbach, Reto A, Brugger, Silvio D, Zinkernagel, Annelies S
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objectives Critically ill coronavirus disease 2019 (COVID‐19) patients are characterised by a severely dysregulated cytokine profile and elevated neutrophil counts, impacting disease severity. However, it remains unclear how neutrophils contribute to pathophysiology during COVID‐19. Here, we assessed the impact of the dysregulated cytokine profile on the regulated cell death (RCD) programme of neutrophils. Methods Regulated cell death phenotype of neutrophils isolated from critically ill COVID‐19 patients or healthy donors and stimulated with COVID‐19 or healthy plasma ex vivo was assessed by flow cytometry, time‐lapse microscopy and cytokine multiplex analysis. Immunohistochemistry of COVID‐19 patients and control biopsies were performed to assess the in situ neutrophil RCD phenotype. Plasma cytokine levels of COVID‐19 patients and healthy donors were measured by multiplex analysis. Clinical parameters were correlated to cytokine levels of COVID‐19 patients. Results COVID‐19 plasma induced a necroptosis‐sensitive neutrophil phenotype, characterised by cell lysis, elevated release of damage‐associated molecular patterns (DAMPs), increased receptor‐interacting serine/threonine‐protein kinase (RIPK) 1 levels and mixed lineage kinase domain‐like pseudokinase (MLKL) involvement. The occurrence of neutrophil necroptosis MLKL axis was further confirmed in COVID‐19 thrombus and lung biopsies. Necroptosis was induced by the tumor necrosis factor receptor 1 (TNFRI)/TNF‐α axis. Moreover, reduction of soluble Fas ligand (sFasL) levels in COVID‐19 patients and hence decreased signalling to Fas directly increased RIPK1 levels, exacerbated TNF‐driven necroptosis and correlated with disease severity, which was abolished in patients treated with glucocorticoids. Conclusion Our results suggest a novel role for sFasL signalling in the TNF‐α‐induced RCD programme in neutrophils during COVID‐19 and a potential therapeutic target to curb inflammation and thus influence disease severity and outcome. This work highlights the role of cell death ambiguity in neutrophils and its contribution to pathophysiology during critical COVID‐19. The inflammatory COVID‐19 environment provoked a TNF‐α‐induced necroptosis‐sensitive neutrophil subpopulation, characterised by elevated release of DAMPs, increased RIPK1 levels and a pivotal role for MLKL. Neutrophil necroptosis through the RIPK1‐RIPK3‐MLKL axis was further confirmed in COVID‐19 thrombus and lung biopsies. Blunted Fas engagement by
ISSN:2050-0068
2050-0068
DOI:10.1002/cti2.1357